Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Financial report summary
?Management Discussion
- Revenue. We generated net revenue of $51.6 million and $53.7 million during the three months ended December 31, 2023 and 2022, respectively. We generated net revenue of $103.0 million and $105.4 million during the six months ended December 31, 2023 and 2022, respectively. Foreign currency fluctuations negatively impacted our revenue $0.2 million, or 0.4% and $0.5 million, or 0.4%, during the three and six months ended December 31, 2023, respectively.
- Revenue in the Americas region for the three and six months ended December 31, 2023 decreased $0.6 million, or 1.6%, and increased $1.5 million, or 2.0%, respectively, from the prior year periods. Total Active Accounts decreased 9.5% in the region compared to the prior year period. The average revenue per account increased due to changes in our product sales mix, driven primarily by our new TrueScience® Liquid Collagen product. Total TrueScience® Liquid Collagen related revenue, including the product when sold as part of a bundle, was approximately $10.5 million and $20.4 million for the three and six months ended December 31, 2023, respectively, compared to approximately $9.3 million and $16.4 million in the prior year periods, respectively.
- Revenue in the Asia/Pacific & Europe region decreased $1.4 million, or 10.0% and $4.0 million, or 13.5%, for the three and six months ended December 31, 2023, respectively as compared to the prior year periods. Total Active Accounts in the region decreased 18.2% compared to the prior year period. Decreases in total Active Accounts, the closure of our e-commerce business in China, along with negative impacts from foreign currency exchange rate fluctuations, have contributed to the overall decrease in revenue within the Asia/Pacific & Europe region.